智通财经APP获悉，花旗发布研报称，药明合联(02268)发盈喜，按国际财务报告准则，预期上半年收入同比增长超过60%，经调整净利润(不含利息收入及开支)增长超过67%，净利润增长逾50%，表现好过市场预期上半年营收和净利分别同比增长52%和26%。营收则符合该行预期，净利较该行预测高出32%。报告指，药明合联管理层将强劲的增长归功于ADC产业的高客户需求、公司拥有高市占率的市场领导地位，以及生产设施利用率的提升。该行重申对药明合联“买入”评级，目标价46港元。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.